Streptomycin (500 mg), standard antimycobacterial drug, was obtained as gift sample from Shalina Laboratories Pvt. Ltd., Navi Mumbai, Maharashtra.
Standard dosing is 75 mg long-acting indomethacin daily, or 25 mg standard release indomethacin three times daily.
Mean daily doses of NSAIDs were 120 mg (standard deviation 29) for diclofenac and 1430 mg (326) for ibuprofen.
Glimepiride was titrated within a 1 4 mg dose range and reached a plateau at 3.0 ± 1.2 mg (standard deviation) from weeks 28 104.
So trials or arms with less than 1.2 mg daily, final dose, were excluded except for one trial[ 18] where liraglutide was used in the dose of 0.6 and 0.9 mg (standard available dose in Japan).
The two "pivotal" treatment trials WV15670 and WV15671 showed a dose-response effect at the 75 mg (standard dose) and 150 mg (high dose) oseltamivir twice daily dose (P=0.038).
Control genomic DNA from corresponding tissues were used for the preparation of calibration curves for the quantification of O-mG and N-mG, with O-mG and N-mG standards added in 40 to 1000 nM.
Since a 1-OH-MG standard was not available, a Gold Standard was used.
For all subjects from the five provinces, the frequency exceeding the Uβ2-MG standard was 14.6 %–58.7 % in males and 14.5 % 65.4%% in females.
Compared to these subjects, a relatively higher frequency exceeded the Uβ2-MG standard was observed in the subjects from the other regions.
The subjects from each province were divided into four groups (UCd: 0 to 2, 2 to 6, 6 to 12 and >12 μg/g cr), and the frequency that exceeded the Uβ2-MG standard were then calculated accordingly.
